(Q41635901)

5 October 2017

1 reference

title

The remarkable spectrum of methotrexate toxicities (English)

1 reference

5 October 2017

1 reference

McKendry RJ

1

1 reference

PubMed ID

9361162

5 October 2017

language of work or name

1 reference

1 November 1997

1 reference

Rheumatic Diseases Clinics of North America

5 October 2017

1 reference

5 October 2017

23

1 reference

5 October 2017

4

1 reference

5 October 2017

939-954

1 reference

Nonperipheral accelerated nodulosis in a methotrexate-treated rheumatoid arthritis patient

5 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Methotrexate in rheumatoid arthritis. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Folic acid and methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Megaloblastic anaemia in psoriatic patients treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

The clinical pharmacology of methotrexate.new applications of an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Methotrexate and trimethoprim-sulphamethoxazole--a potentially hazardous combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Postinjection nonvasomotor reactions during chrysotherapy. Constitutional and rheumatic symptoms following injections of gold salts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Small-vessel vasculitis and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Acute parvovirus B19-induced pancytopenia in the setting of methotrexate therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Methotrexate osteopathy in rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Methotrexate osteopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Folate supplementation in methotrexate-treated rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

In vitro effects of methotrexate on human articular cartilage and bone-derived osteoblasts.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Efficacy of low-dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Central nervous system toxicity associated with weekly low-dose methotrexate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970367-7

7 January 2021

10.1016/S0889-857X(05)70367-7

Identifiers

DOI

1 reference

5 October 2017

1 reference

PubMed ID

9361162